目的 建立小肠灌流液中头孢克洛的高效液相色谱(HPLC)分析方法, 考察蒲地蓝消炎口服液对头孢克洛在大鼠小肠吸收的影响, 为临床联合用药的合理性提供实验依据。方法 采用大鼠在体单向肠灌流实验模型, 应用重量法校正灌流液体积, HPLC测定灌流液中头孢克洛, 计算头孢克洛肠吸收参数。结果 头孢克洛在各肠段均有良好吸收, 小肠不同部位头孢克洛的吸收速率常数(K_a)与有效渗透系数(P_eff)大小为十二指肠> 空肠≈回肠, 各肠段间的吸收无统计学差异;联合应用蒲地蓝消炎口服液时, 头孢克洛在全场段的吸收均有所减少, 十二指肠处显著减少(P<0.05), 其他肠段处无统计学差异(P> 0.05)。结论 研究结果表明蒲地蓝消炎口服液会影响头孢克洛的小肠吸收, 因此两药联合使用时产生较好的药效不是通过促进头孢克洛的吸收而实现的, 而是二者共同作用的结果。

Objective To establish a method for the determination of cefaclor by HPLC and to investigate the effects of Pudilan on intestinal absorption of cefaclor in rats. Methods The rat single-pass intestinal perfusion technique was applied to investigatting the intestinal absorption of cefaclor, and the gravimetry was used to correct the perfusion volume. After the concentration of cefaclor in perfusate was determined by HPLC, the absorption parameters of cefaclor were calculated. Results Cefaclor was absorbed well in all parts of the small intestine. The absorption rate constants (K_a) and the effective permeability coefficients (P_eff) of cefaclor were ordered as follows: duodenum > jejunum ≈ ileum. There was no significant indifference in each segment (P > 0.05). When cefaclor was used combining with Pudilan together, the values of K_a and P_eff decreased in all segments and especially in duodenum (P < 0.05) comparing with using cefaclor only. Besides no significant difference in the parameters was found in jejunum and ileum (P > 0.05). Conclusion The above findings reveal that the intestinal absorption of cefaclor could be affected by Pudilan. Therefore the combined application of the two drugs has better efficacy which is not accomplished by promoting the absorption of cefaclor, while it may be the result of the synergic action of the two drugs.